(AOF) – Poxel today announces its participation in the 12th International Meeting on AMPK, on October 4. Sophie Bozec, Executive Vice President, Pharmacology & Scientific Communication, will give a virtual presentation focused on PXL770, a molecule owned by Poxel, whose development targets rare diseases, including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).
This presentation will focus on PXL770, a molecule owned by Poxel, which is a first-in-class direct activator of adenosine monophosphate-activated protein kinase (AMPK) and whose development targets rare diseases, including adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD).
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
